The efficacy of TAMUS 2032 in preventing a natural outbreak of colibacillosis in broiler chickens in floor pens.
A 42-d floor pen study was conducted with broiler chickens comparing the effects on bird performance of 12 ppm TAMUS 2032 (also known as BT) and 55 ppm bacitracin methylene disalicyclate (BMD) when fed alone or in combination with 99 ppm monensin (MON). Unmedicated and 99 ppm MON treatments were included in the study design. Beginning on d 22 of study, birds in all 6 treatments were subjected to a modulated house temperature and airflow to mimic conditions conducive to outbreaks of colibacillosis. A natural outbreak of colibacillosis developed beginning on d 27. Primary lesions in dead birds included airsacculitis and pericarditis with occasional findings of perihepatitis. At d 42 of study, means for weight gain in the TAMUS 2032 and TAMUS 2032 + MON treatments were greater in comparison with the unmedicated and BMD treatments, and means for feed conversion for both treatments were improved in comparison with the unmedicated treatment. Mean feed conversion in the TAMUS 2032 + MON treatment was also improved in comparison with BMD treatment. Mortality due to colibacillosis was reduced in the TAMUS 2032 (0.051%), TAMUS 2032 + MON (0.642%), and MON + BMD (1.515%) treatments in comparison with the unmedicated treatment (13.402%) and the BMD treatment (11.159%). The results of improved performance and reduced mortality indicated that 12 ppm TAMUS 2032 was highly efficacious against colibacillosis in growing chickens. The reduced mortality percentages in the MON + BMD treatment indicated that this combination also provided a good level of protection against the natural outbreak of colibacillosis.
Jiang
Y W
YW
Department of Medical Biochemistry & Genetics, Texas A&M University System Health Science Center, 428 Reynolds Medical Building, College Station, Texas 77843-1114, USA. ywjiang@medicine.tamhsc.edu
Sims
M D
MD
Conway
D P
DP
D000818:Animals; D001414:Bacitracin / Q000627:therapeutic use; D002645:Chickens / Q000382:microbiology; D004196:Disease Outbreaks / Q000517:prevention & control* / Q000662:veterinary*; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D006520:Hepatitis, Animal / Q000150:complications; D006358:Hot Temperature; D006799:Housing, Animal; D008297:Male; D008985:Monensin / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use*; D010493:Pericarditis / Q000150:complications / Q000662:veterinary; D011201:Poultry Diseases / Q000382:microbiology* / Q000473:pathology / Q000517:prevention & control*; D012459:Salicylates / Q000627:therapeutic use; D014691:Ventilation
C507515:BT peptide antibiotic, Brevibacillus texasporus; D009842:Oligopeptides; D012459:Salicylates; D001414:Bacitracin; D008985:Monensin; C023400:bacitracin methylenedisalicylic acid